De-nest and present filled glass vials for inspection in aseptic fill-finish
AstraZeneca runs aseptic fill-finish across multiple sites (e.g. sterile injectables such as Zoladex at Macclesfield, vial/syringe filling for the planned ADC plant in Singapore, and historically the West Chester vial/syringe/cartridge facility), where filled glass vials must be removed from nest trays, oriented and presented to inspection and downstream capping/labelling. The objects are thin-walled, fragile, often cold and wet filled glass vials whose contents are high-value sterile drug product. The task sits between filling and inspection/packaging in a controlled aseptic environment. It is hard for a robot because a force-blind grasp can chip or crack the glass, and a wet/cold vial can slip; both create particulate, breakage or contamination events. Volume can be very high (the North Ryde site alone runs lines rated at tens of millions of units annually), making consistent gentle handling a real throughput-and-quality lever. We identified this through our own research; we have not confirmed the specifics with the customer directly. This page is our researched read — a starting point for that conversation.
What the task is
RESEARCHED · our reconstructionAstraZeneca runs aseptic fill-finish across multiple sites (e.g. sterile injectables such as Zoladex at Macclesfield, vial/syringe filling for the planned ADC plant in Singapore, and historically the West Chester vial/syringe/cartridge facility), where filled glass vials must be removed from nest trays, oriented and presented to inspection and downstream capping/labelling. The objects are thin-walled, fragile, often cold and wet filled glass vials whose contents are high-value sterile drug product. The task sits between filling and inspection/packaging in a controlled aseptic environment. It is hard for a robot because a force-blind grasp can chip or crack the glass, and a wet/cold vial can slip; both create particulate, breakage or contamination events. Volume can be very high (the North Ryde site alone runs lines rated at tens of millions of units annually), making consistent gentle handling a real throughput-and-quality lever.
Is this the actual task and sequence? What are the real tolerances, cycle rate, and reject criteria, and which steps are today's manual bottleneck? Answering these is what turns this from a researched signal into a validated use case.